NOD mouse model for Sjögren's syndrome: lack of longitudinal stability
- 20 October 2006
- journal article
- Published by Wiley in Oral Diseases
- Vol. 12 (6) , 566-572
- https://doi.org/10.1111/j.1601-0825.2006.01241.x
Abstract
OBJECTIVES: The non-obese diabetic (NOD) mouse is not only a widely used model for diabetes mellitus type I, but also for the chronic autoimmune disease Sjögren's syndrome (SS), mainly affecting salivary and lacrimal glands. We studied the efficacy of local recombinant serotype 2 adeno-associated viral (rAAV2) vector transfer of immunomodulatory transgenes to alter the SS-like disease in NOD mice. Data collected over a 2-year period indicated a changing SS phenotype in these mice and this phenomenon was investigated. METHODS: 10(10) particles rAAV2LacZ/gland were delivered to both submandibular glands (SMGs) of NOD/LtJ mice at 8 weeks (before sialadenitis onset) of age. Salivary flow rates were determined at 8 weeks and time of killing. Blood glucose levels and body weights were measured weekly. After killing, saliva and SMGs were harvested. Analyses of salivary output, inflammatory infiltrates (focus score), SMG cytokine profile, body weight, and diabetes mellitus status were performed. Data from six different experimental studies over 2 years were analyzed and compared. RESULTS: Salivary flow rate, focus score, and SMG cytokines interleukin (IL)-2, IL-4, IL-6, IL-10, IL-12(p70), tumor necrosis factor-alpha and IFNgamma showed changes over time. There were no differences for body weight, diabetes mellitus prevalence, or blood glucose level of non-diabetic mice. CONCLUSION: This retrospective report is the first to describe longitudinal variability in the NOD mouse as a model for SS. We advise other investigators to continuously monitor the SS phenotype parameters and include appropriate controls when studying this disease in NOD micKeywords
This publication has 31 references indexed in Scilit:
- THE NOD MOUSE: A Model of Immune DysregulationAnnual Review of Immunology, 2005
- Recombinant adeno-associated virus vectors for gene therapyExpert Opinion on Biological Therapy, 2004
- Immunopathogenesis of Sjögren's SyndromeClinical Reviews in Allergy & Immunology, 2003
- Two NOD Idd‐associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjögren's syndrome) on a healthy murine backgroundArthritis & Rheumatism, 2002
- Progress in Understanding Autoimmune Exocrinopathy Using the Non-obese Diabetic Mouse: An UpdateCritical Reviews in Oral Biology & Medicine, 2002
- Adenoassociated Virus-Mediated Transfer of a Functional Water Channel into Salivary Epithelial CellsIn VitroandIn VivoHuman Gene Therapy, 1998
- High-Efficiency Transfer of the T Cell Co-Stimulatory Molecule B7-2 to Lymphoid Cells Using High-Titer Recombinant Adeno-Associated Virus VectorsHuman Gene Therapy, 1995
- Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human diseaseImmunology Today, 1994
- Group size, cage shelf level, and emotionality in non-obese diabetic mice: impact on onset and incidence of IDDM.Psychosomatic Medicine, 1991
- High and Low Diabetes Incidence Nonobese Diabetic (NOD) Mice: Origins and CharacterisationAutoimmunity, 1991